Established · publishing since 1997Rising activity
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Publications
859
Citations
43,073
Est. group size
~4
Recurring co-author estimate
Active years
30
Publishing since 1997
In context
Among 4,953 established Medicine PIs within our index
Citations: 43,073p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 78.8p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~17 · 5% small-team papers (≤3 authors) · across 67 venues
Publication cadence
Publications per year over the last 10 years — averaging 78.8/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Abstract 406: Discovery of potent and selective TRIB2 inhibitors with therapeutic efficacy in therapy-resistant neuroendocrine prostate cancer.
Cancer Research · 2026
- Table S6 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Figure S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
2026
- Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non–Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population
JCO Global Oncology · 2026
- Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic Non‒Small-Cell Lung Cancer With KRAS G12C Mutation: Results of a Phase 1b Study
JTO Clinical and Research Reports · 2026
- Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine · 2025
Publishes in
- Journal of Clinical Oncology×94
- Journal of Thoracic Oncology×78
- Annals of Oncology×38
- Cancer Research×28
- Clinical Lung Cancer×17
Similar researchers
By research-topic overlap
- Nobuyuki Yamamoto
Medicine · Indiana University
- Tamio Okimoto
Medicine · The Ohio State University
- Gregory A. Otterson
Medicine · The Ohio State University
- Nasser H. Hanna
Medicine · Indiana University
- Po‐Lan Su
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile